Accessing Diverse Patient Populations through Clinical Trial Diversity and Inclusion Data
Despite recent guidelines from the Food & Drug Administration on reaching diverse and underserved patient populations for clinical trials, the industry as a whole is still severely lagging in making real progress. A recent issue of STAT news noted that in an FDA analysis between 2014 and 2021 fewer than 14% of drugs had clinical trial data regarding treatment benefits or side effects for Black patients.
As a step towards diversifying both trial participants and site investigators, H1 provides in-depth analysis on clinical trials to provide an external resource for companies to be able to run more equitable trials that represent the patient populations the drugs seek to help. With H1, clinical and medical teams are empowered to make impactful decisions by recognising available research sites, potential trial investigators by assessing the global clinical and competitive landscape. Speeding up every step of the clinical process - from early phase clinical research all the way to drug launch - by supporting data-driven decision making based on continuously updated global insights.
Recently, an H1 client was struggling to find new potential Primary Investigators and clinical trial sites in specific regions. Their primary goal was to find HCPs with the right experience levels, and with access to diverse patient populations in immunology for an upcoming clinical trial.
This client had already exhausted their internal resources, but did not have any information supporting their diversity needs. They wanted to understand if any of their internally identified investigators and sites had access to a diverse patient population, while also attempting to discover if there were other people or sites matching their criteria of which they were currently unaware. How did they fare?